Nicolas Villain
@nvillain-alz.bsky.social
Neurologue Chercheur | Neurologist Researcher | #Alzheimer #Dementia #Neurodegeneration | @fac-sante-sorbonne.bsky.social | @sorbonne-universite.fr | @pitiesalpetriere.bsky.social | @ap-hp.bsky.social | @institutducerveau.bsky.social
Reposted by Nicolas Villain
Part 1 focused on patient selection challenges. Part 2 will focus on health system readiness. Tara Carlisle and myself were co-first authors on these and benefited greatly from our senior author, Kirk Daffner.
May 7, 2025 at 4:51 PM
Part 1 focused on patient selection challenges. Part 2 will focus on health system readiness. Tara Carlisle and myself were co-first authors on these and benefited greatly from our senior author, Kirk Daffner.
Absolutely! I'm celebrating for the 85%! :)
April 15, 2025 at 6:58 PM
Absolutely! I'm celebrating for the 85%! :)
The favorable R/B ratio remains*
April 15, 2025 at 6:40 PM
The favorable R/B ratio remains*
It could also be argued that this subgroup hasn't proved efficacy. Therefore, the R/B ratio remains to be proven considering the significant safety signal
April 15, 2025 at 6:38 PM
It could also be argued that this subgroup hasn't proved efficacy. Therefore, the R/B ratio remains to be proven considering the significant safety signal
2/
C) The key question: if excluded from treatment, what enhanced support/follow-up do we offer? What research for this vulnerable group?
The APOLLOE4 trial is an example of an active engagement into this direction!
C) The key question: if excluded from treatment, what enhanced support/follow-up do we offer? What research for this vulnerable group?
The APOLLOE4 trial is an example of an active engagement into this direction!
April 15, 2025 at 5:04 PM
2/
C) The key question: if excluded from treatment, what enhanced support/follow-up do we offer? What research for this vulnerable group?
The APOLLOE4 trial is an example of an active engagement into this direction!
C) The key question: if excluded from treatment, what enhanced support/follow-up do we offer? What research for this vulnerable group?
The APOLLOE4 trial is an example of an active engagement into this direction!
1/ Indeed, an important milestone with EMA approval of lecanemab! Is it genetic discrimination? I beg to disagree :)
A) Not all inequality is inequity — in oncology, genetics often guides access.
B) Feels like double jeopardy: highest risk, yet denied treatment. But safety data matters.
A) Not all inequality is inequity — in oncology, genetics often guides access.
B) Feels like double jeopardy: highest risk, yet denied treatment. But safety data matters.
April 15, 2025 at 5:04 PM
1/ Indeed, an important milestone with EMA approval of lecanemab! Is it genetic discrimination? I beg to disagree :)
A) Not all inequality is inequity — in oncology, genetics often guides access.
B) Feels like double jeopardy: highest risk, yet denied treatment. But safety data matters.
A) Not all inequality is inequity — in oncology, genetics often guides access.
B) Feels like double jeopardy: highest risk, yet denied treatment. But safety data matters.
I mean, now the decision relies on the European Commission directly as the dedicated committees could not make a decision
April 15, 2025 at 5:47 AM
I mean, now the decision relies on the European Commission directly as the dedicated committees could not make a decision
« The European Commission (EC) is the primary executive arm of the European Union (EU). It operates as a cabinet government »
en.wikipedia.org/wiki/Europea...
en.wikipedia.org/wiki/Europea...
European Commission - Wikipedia
en.wikipedia.org
April 15, 2025 at 5:42 AM
« The European Commission (EC) is the primary executive arm of the European Union (EU). It operates as a cabinet government »
en.wikipedia.org/wiki/Europea...
en.wikipedia.org/wiki/Europea...
10/ The science is on the table. The @ema.europa.eu's CHMP has spoken. The clinics are ready. It’s time for the @ec.europa.eu to act.
#Alzheimers #EuropeanCommission #lecanemab #EMA #neurology
#Alzheimers #EuropeanCommission #lecanemab #EMA #neurology
April 14, 2025 at 1:46 PM
10/ The science is on the table. The @ema.europa.eu's CHMP has spoken. The clinics are ready. It’s time for the @ec.europa.eu to act.
#Alzheimers #EuropeanCommission #lecanemab #EMA #neurology
#Alzheimers #EuropeanCommission #lecanemab #EMA #neurology